Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences [HumanMethylationEPICv2]
Ontology highlight
ABSTRACT: In the WSG-ADAPT trial (NCT01779206), HR+/HER2-EBC patients underwent pre-operative short-term endocrine therapy (pET). Treatment response was determined by immunohistochemical in-situ labeling of cycling cells (G1 to M-phase) with Ki67 before and after pET. We performed Infinium MethylationEPICv2-based DNA methylation analysis post-pET in a validation cohort2 (n=176, unmatched). Predictive indices of endocrine resistance under both treatments were calculated as described in medRxiv 2023.11.13.23298466; doi: https://doi.org/10.1101/2023.11.13.23298466
ORGANISM(S): Homo sapiens
PROVIDER: GSE274415 | GEO | 2025/07/17
REPOSITORIES: GEO
ACCESS DATA